The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Dibirov M.D.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, City Clinical hospital named after S.I. Spasokukotskyi

Khachatrian N.N.

Kafedra obshcheĭ khirurgii Pervogo moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova

Isaev A.I.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, City Clinical hospital named after S.I. Spasokukotskyi

Karsotyan G.S.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, City Clinical hospital named after S.I. Spasokukotskyi

Alimova E.E.

Moscow city hospital named after S.I. Spasokukotskiy, Moscow, Russia

Kostyuk E.A.

Moscow city hospital named after S.I. Spasokukotskiy, Moscow, Russia

New possibilities in antibacterial treatment of intra-abdominal infections caused by multiresistant microflora

Authors:

Dibirov M.D., Khachatrian N.N., Isaev A.I., Karsotyan G.S., Alimova E.E., Kostyuk E.A.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2019;(12): 74‑83

DOI: 10.17116/hirurgia201912174

Views: 3698

Downloaded: 118

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Dibirov MD, Khachatrian NN, Isaev AI, Karsotyan GS, Alimova EE, Kostyuk EA. New possibilities in antibacterial treatment of intra-abdominal infections caused by multiresistant microflora. Pirogov Russian Journal of Surgery. 2019;(12):74‑83. (In Russ.)
https://doi.org/10.17116/hirurgia201912174

Подписка 2025 (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Close metadata

Aim — to determine the place of new drugs with activity against multidrug resistant strains of microorganisms in the treatment of complicated intraabdominal infections. Material and methods. The incidence and distribution of pathogens isolated from intra-abdominal specimens in patients with intra-abdominal infections are analyzed. Results. The current situation on the growth of resistant strains among pathogens causing intra-abdominal infections is rewied. New combined drugs for the treatment of multidrug resistant infections — ceftolozane/tazobactam and ceftazidim/avibactam plus metronidazole, has been suggested. Their potential role in empiric and targeted antibacterial treatment of complicated intraabdominal infections is defined. Conclusion. Taking into consideration local monitoring data and risk factors of multi resistant strains Ceftolozane/tazobactam in combination with metronidazole can be used in empiric regime of treatment. Due to the high activity on carbapenem resistant strains of Klebsiella pneumonia and the lack of alternatives, it is advisable to use Ceftazidim/avibactam for the targeted therapy.

Keywords:

intra-abdominal infections
microbial resistance
carbapenems
ceftolozane/tazobactam
ceftazidim/avibactam
multidrug resistant strains
Enterobacteriales
Pseudomonas aeruginosa

Authors:

Dibirov M.D.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, City Clinical hospital named after S.I. Spasokukotskyi

Khachatrian N.N.

Kafedra obshcheĭ khirurgii Pervogo moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova

Isaev A.I.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, City Clinical hospital named after S.I. Spasokukotskyi

Karsotyan G.S.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, City Clinical hospital named after S.I. Spasokukotskyi

Alimova E.E.

Moscow city hospital named after S.I. Spasokukotskiy, Moscow, Russia

Kostyuk E.A.

Moscow city hospital named after S.I. Spasokukotskiy, Moscow, Russia

List of references:

  1. Intra-abdominal surgical infections. Russian National guidelines. Eds. Gelfand BR, Kirienko AI, Khachatryan NN. Moscow: MIA, 2018;164. (In Russ.)
  2. Skleenova EYu, Azizov IS, Shek EA, Edelstein MV, Kozlov RS, Dekhnich AV. Pseudomonas aeruginosa: the history of one of the most successful nosocomial pathogens in Russian hospitals. Clinical microbiology and antimicrobial chemotherapy.2018;20(3):164-171. (In Russ.) https://doi.org/10:36488
  3. Strategy and tactics of the use of antimicrobial drugs in medical institutions. Russian national guidelines. Eds. Savelyev VS, Gelfand BR, Yakovlev SV. M. 2012. (In Russ.) ISBN 978-5-91482-024-1
  4. Kusmenkov AYu, Trushin IV, Avramenko AA, Eydelshteyn MV, Dekhnich AV, Koslov RS. AMRMAP: Internet platform of monitoring the antibiotic resistance. Clinical microbiology and antimicrobial chemotherapy. 2017;19(2):84-90. (In Russ.)
  5. Bassetti Matteo, Peghin Maddalena, Vena Antonio, Giacobbe Daniele Roberto Treatment of Infections Due to MDR Gram-negative Bacteria. Frontiers in Medicine. 2019 Apr, 6(74):1-10. https://doi.org/10.3389/fmed.2019.00074
  6. Carmelli Y, Armstrong J, Laud PJ, et al Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (RE-PRISE): a randomized, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016 April 20;1473-3099. https://doi.org/10.1016/S1473-3099(16)30004-4
  7. Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother. 2014;58:6844-6850. https://doi.org/10.1128/AAC.00825-15
  8. Clowes A, Lam M, Hamula C, Dingle T. In vitro susceptibility of a collection of car-bapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Ceftazidime/Avibactam and Ceftolozane/tazobactam. ASM Microbe. 2016 (Boston, MA). Abstract 480.
  9. Eckmann C, Solomkin J. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother. 2015;16:271-280. https://doi.org/10.1517/14656566.2015.994504
  10. Farrell DJ, Flamm RK, Castanheira M, Jones RN. Antimicrobial Activity of Ceftolozane/Tazobactam from the PACTS Programme Tested against Enterobacteriaceae Isolated from Patients Hospitalized in Intensive Care Units from 19 European Countries, Turkey and Israel (2013-2014). European Society of Clinical Microbiology and Infectious Diseases (ECCMID). 2016;Poster P-0339.
  11. Farrell DJ, Flamm RK, Castanheira M, Jones RN. Antimicrobial Activity of Ceftolozane/Tazobactam from the PACTS Programme Tested against Pseudomonas aeruginosa Isolated from Patients Hospitalised in Intensive Care Units in Europe, Turkey and Israel (2013-2014). European Society of Clinical Microbiology and Infectious Diseases (ECCMID). 2016;Poster P-0340.
  12. Ghady Haidar, Nathan J. Philips, Ryan K. Shields et al. Ceftolozane-Tazobactam for the Treatment of multidrug resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clinical Infectious Diseases. 2017;65(1):110-120. https://doi.org/10.1093/cid/cix182
  13. Giancola SE, Mahoney MV, Bias TE, Hirsch EB. Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections. Ther Clin Risk Manag. 2016;12:787-797. https://doi.org/10.2147/TCRM.S83844
  14. Grunau G, Heemken R, Hau T. Predictors of outcome in patients with postoperative intra-abdominal infection. Eur J Surg. 1996;162;619-625.
  15. Sader HS, Farrell DJ, et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and USA hospitals. Journal of Infection. 2014;69:266-277. https://doi.org/10.1016/j.jinf.2014.04.004
  16. Kazmierczak K, LOB Sibylle, Raddatz J, et al. Activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical Paeruginosa isolates collected in United States and Canada — SMART 2018. IDWeek 2019 P718.
  17. Koperna T, Schulz F. Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg. 2000;24:32-37. https://doi.org/10.1007/s002689910007
  18. Lahiri SD, Johnstone MR, Ross P L., McLaughlin RE, Olivier NB, et al. Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance. Antimicrob Agents Chemother. 2014;58:5704-5713. https://doi.org/10.1128/AAC.03057-14
  19. May AK. PS204. The Bad Infections: Tools to Keep Ahead of Difficult Infections and Resistant Organisms Tuesday. 2015 October 6, FACS.
  20. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole versus Meropenem in the Treatment of Complicated Intra-Abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis. 2016;62:1380-1389. https://doi.org/10.1093/cid/ciw133
  21. Miller B, Popejoy MW, Hershberger E, Steenbergen JN, Alverdy J. Characteristics and outcomes of complicated intra-abdominal ingections involving Pseudomonas aeruginosa from a Randomized double-blind, Phase 3 Ceftolozane/Tazobactam study. Antimicrobial Agents and Chemotherapy. 2016 July;60(7):4387-4390. https://doi.org/10.1128/AAC.03074-15
  22. Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel). 2013;6:1335-1346. https://doi.org/10.3390/ph6111335
  23. Quarshie C, Bobbili K, Lawhorn J, Koirala J. Susceptibility of carbapenem-resistant Acinetobacter baumanii and Pseudomonas aeruginosa to cephalosporin and beta-lactamase inhibitor combinations. ASM Microbe. 2016 (Boston, MA), Abstract 253.
  24. Sader HS, Farrell DJ, et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intraabdominal and urinary tract infections in European and USA hospitals. Journal of Infection. 2014;69:266-277. https://doi.org/10.1016/j.jinf.2014.04.004
  25. Sader HS, Castanheira M, Flamm RK, et al. Ceftazidim-avibactam Activity tested against aerobic gram-negative organisms isolated from intra-abdominal infections in United States Hospitals (2012-2014). ICAAC. 2015.
  26. Sartelli Massimo, Chichom-Melife Alain, Labricciosa F, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World Journal of Emergency Surgery. 2017;12:29. https://doi.org/10.1186/s13017-017-0141-6
  27. Sartelli Massimo, Catena Fausto, Ansaloni Luca, et al. Complicated intra-abdominal infections in Europe: preliminary data from the first three months of the CIAO Study. World journal of Emergency Surgery. 2012;7-15. https://doi.org/10.1186/1749-7922-7-15
  28. Seiler CA, Brugger L, Forssmann U, Baer HU, Buchler MW. Conservative surgical treatment of diffuse peritonitis. Surgery. 2000;127:178-184. (PubMed) https://doi.org/10.1067/msy.2000.101583
  29. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61:e00883-17. https://doi.org/10.1128/AAC.00883-17
  30. Skalweit MJ. Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections. Drug design, Development and therapy. 2015;9:2919-2925. https://doi.org/10.2147/DDDT.S61436
  31. Sneed D, Van Horn KG. Comparison of the in vitro activity of ceftolozane-tazobactam and Ceftazidime-avibactam against Ceftazidime non-susceptible Pseudomonas aeruginosa. ASM Microbe. 2016 (Boston, MA), Abstract 255.
  32. Solomkin JS, Ristagno RL, Das AF, Cone JB, Wilson SE, Rotstein OD, Murphy BS, Severin KS, Bruss JB. Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections. Clin Infect Dis. 2013;56(12):1765-1773. https://doi.org/10.1093/cid/cit128
  33. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/ tazobactam plus metronidazole for complicated intraabdominal infections in an era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462-1471. https://doi.org/10.1093/cid/civ097
  34. Takesue Yoshio, Shinya Kusachi, Hiroshige Mikamo, et al. Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infection in Japan. Journal of Infection and Chemotherapy. 2018;24:330-340. https://doi.org/10.1016/j.jiac.2018.02.011
  35. Titelman E, Karlsson IM, Ge Y, Giske CG. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2011;70:137-141. https://doi.org/10.1016/j.diagmicrobio.2011.02.004
  36. Veeraraghavan Balaji, Mark Ranjan Jesudason, John Antony Jude Prakasah, Shalini Anandan, Rani Diana Sahni, Agila Kumari Pragasam, Yamuna Devi Bakthavatchalam, Rajesh Joseph Selvakumar, TN Dhole, Camilla Rodrigues, Indranil Roy, Sangeetha Joshi, Bhaskar Narayan Chaudhuri, DS Chitnis Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014-2016: Study for monitoring antimicrobial resistance trend report. Indian Journal of Medical Microbiology. 2018.
  37. Zavicefta [Summary of Product Characteristics]. Södertälje, Sweden: AstraZeneca AB. Accessed August 24. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004027/WC500210234.pdf
  38. ZERBAXA [Company Core Data Sheet] 2015. Kenilworth, NJ, USA: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
  39. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73:159-177. https://doi.org/10.1007/s40265-013-0013-7
  40. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP3rd, Karlowsky JA. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31-51. https://doi.org/10.1007/s40265-013-0168-2

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.